EMJ Dermatology 9 [Supplement 1] . 2021

At the 2020 European Academy of Dermatology and Venerology (EADV) Virtual Congress, data for 5-year efficacy and safety of tildrakizumab in adults with moderate-to-severe plaque psoriasis were presented across six posters. Overall, it was shown that tildrakizumab has a very favourable long-term efficacy and safety profile.